Clinical Trial

The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-22.
Status change: Not Yet Recruiting → Recruiting 2026-03-20
Trial Details
NCT Number NCT07138755
Lead Sponsor The Third Xiangya Hospital of Central South University
Conditions NSCLC, Sintilimab, Adaptive Radiotherapy
Enrollment 35 participants
Start Date 2025-08-29
Primary Completion 2028-12 (estimated)
Study Completion 2030-09 (estimated)
Updated on ClinicalTrials.gov 2026-03-25